Meeting Banner
Abstract #1691

LI-RADS treatment response criteria for hepatocellular carcinoma after locoregional treatment on contrast-enhanced CT and gadoxetic acid-enhanced MRI: a retrospective validation study using pathologic diagnosis as the reference standard

Sungeun Park1,2, Ijin Joo1, Dong Ho Lee1, Jae Seok Bae1, Jeongin Yoo1, and Joon Koo Han1,2,3

1Department of Radiology, Seoul National University Hospital, Seoul, Korea, Republic of, 2Department of Radiology, Seoul National University College of Medicine, Seoul, Korea, Republic of, 3Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea, Republic of

The liver imaging reporting and data system (LI-RADS) recently introduced a new treatment response algorithm, namely LI-RADS treatment response (LR-TR), for HCCs treated with locoregional therapy. Using pathologic tumor viability as the reference standard, our study showed that LR-TR viable category resulted in sensitivities of 67.3%/74.5% on CT and 75.5%/80.9% on Gd-EOB-MRI; and specificities of 88.6%/88.6% on CT and 80.0%/82.9% on Gd-EOB-MRI, in reviewers 1/2, respectively, which were not significantly different between CT and Gd-EOB-MRI. In addition, our modified TR criteria applying MRI ancillary features demonstrated significantly higher sensitivity (83.6%/88.2%) and comparable specificity (80.0%/77.1%) than LR-TR on CT or MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here